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Introduction
Nanoparticles have attracted much attention for their potential
application as in vivo carriers of active principles. The use of
liposomes as drug carrier systems was proposed by Gregoria-
dis and Ryman in the early 70s.[1] These supramolecular aggre-
gates are nontoxic, biodegradable, and non-immunogenic. Be-
cause of their size, which typically ranges in mean diameter
from 50–300 nm, liposomes display unique pharmacokinetic
properties. These include clearance via the reticuloendothelial
system, which results in a relatively long systemic circulation
time, as well as hepatic and splenic distribution. Furthermore,
liposomes exhibit preferential extravasation and accumulation
at the site of solid tumors due to the increased endothelial
permeability and reduced lymphatic drainage in these tissues,
which has been defined as the enhanced permeability and re-
tention effect (EPR).[2–5] The hydrophobic core of micelles and
inner cavity of liposomes are carrier compartments which are
able to accommodate large amount of drugs, while the shell,
consisting of brush-like protective corona, stabilizes them in
physiological or serum conditions and reduces toxicity of the
active principle in non-target organs. Thus, associating a drug
with liposomes markedly changes its pharmacokinetic and
pharmacodynamic properties and lowers systemic toxicity; fur-
thermore, the drug is prevented from early degradation and/or
inactivation following introduction to the target organism.[6–9]
In systemic administration, micelles or liposomes should satisfy
several base requirements: high drug loading, biodegradability,
long blood circulation times, slow plasma clearance, and con-
trollable drug release profiles.
Many research efforts have been directed towards improving
the safety profile of the cytotoxic anthracyclines doxorubicin,
daunorubicin, and vincristine, which are associated with severe
cardiotoxic side effects. For example, the alkylating agent dox-
orubicin acts by intercalating DNA and has been used in the
liposomal formulation known as Doxil for ovarian cancer treat-
ment. Doxil exhibited increased circulation time and decreased
cardiovascular-related toxicity as compared to free doxorubi-
cin,[10] while encapsulated doxorubicin liposomes, combined
with cyclophosphamide, showed high antitumor effects in an
experimental pulmonary metastatic melanoma mouse
model.[11] Labeling of nanoparticles with bioactive markers that
are able to direct them toward specific biological target recep-
The structure and the in vitro behavior of liposomes filled with
the cytotoxic drug doxorubicin (Doxo) and functionalized on
the external surface with a branched moiety containing four
copies of the 8–13 neurotensin (NT) peptide is reported. The
new functionalized liposomes, DOPC-NT4Lys(C18)2, are obtained
by co-aggregation of the DOPC phospholipid with a new syn-
thetic amphiphilic molecule, NT4Lys(C18)2, which contains a
lysine scaffold derivatized with a lipophilic moiety and a tetra-
branched hydrophilic peptide, NT8–13, a neurotensin peptide
fragment well known for its ability to mimic the neurotensin
peptide in receptor binding ability. Dynamic light scattering
measurements indicate a value for the hydrodynamic radius
(RH) of 88.34.4 nm. The selective internalization and cytotox-
icity of DOPC-NT4Lys(C18)2 liposomes containing Doxo, as com-
pared to pure DOPC liposomes, were tested in HT29 human
colon adenocarcinoma and TE671 human rhabdomyosarcoma
cells, both of which express neurotensin receptors. Peptide-
functionalized liposomes show a clear advantage in compari-
son to pure DOPC liposomes with regard to drug internaliza-
tion in both HT29 and TE671 tumor cells : FACS analysis indi-
cates an increase in fluorescence signal of the NT4-liposomes,
compared to the DOPC pure analogues, in both cell lines; cy-
totoxicity of DOPC-NT4Lys(C18)2-Doxo liposomes is increased
four-fold with respect to DOPC-Doxo liposomes in both HT29
and TE671 cell lines. These effects could to be ascribed to the
higher rate of internalization for DOPC-NT4Lys(C18)2-Doxo lipo-
somes, due to stronger binding driven by a lower dissociation
constant of the NT4-liposomes that bind the membrane onto a
specific protein, in contrast to DOPC liposomes, which ap-
proach the plasma membrane unselectively.
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tors has led to a new generation of delivery systems for active
principles.[12] Peptides and antibodies are the bioactive markers
commonly used to prepare target-selective supramolecular ag-
gregates, such as micelles and liposomes.[13–15] In particular,
low-molecular-weight peptides that remain stable in vivo, well-
exposed on the aggregate surface, and in appropriate confor-
mation for binding, could be promising tools to selectively de-
liver nanoparticles filled with active components to the cellular
target. The peptides could act to target neovascularization
sites in angiogenic processes or membrane receptors overex-
pressed in cancer cells. Receptors for various endogenous pep-
tides are overexpressed in several human tumors and can be
used as tumor antigens.[16] In the last decade, a number of dif-
ferent derivatives of somatostatin, luteinizing hormone-releas-
ing hormone (LHRH), bombesin,[17] cholecystokinin,[18] neuro-
tensin, and neuropeptide Y[19] have been used to target tumor
cells.
We have been studying the use of tetrabranched peptides
(NT4) that contain the sequence of the human regulatory pep-
tide neurotensin (NT) as tumor targeting agents. NT is a 13
amino acid peptide originally isolated from calf hypothalamus,
the full amino acid sequence is QLYENKPRRPYIL, with the C-
terminus is comprised of short active fragment 8–13
(RRPYIL). NT has the dual functions of neurotransmitter or
neuromodulator in the nervous system and local hormone in
the periphery. NT receptor type 1 (NTS1) is overexpressed in
severe malignancies such as small cell lung cancer and colon,
pancreatic, and prostate carcinomas.[16,19] NT has additional
well-established targets on the cell surface: NT receptor 2, NT
receptor 3 (NTR3, or Sortilin), and SorLA (LR11); these latter
two membrane proteins belong to the novel Vps10p-domain
family.[20] Importantly, Sortilin has recently been described as
having an important role in pancreatic ductal adenocarcinoma
tumor cells.[21]
It is well known that peptides synthesized in a branched
form not only become resistant to proteases but also increase
linear peptide biological activity through multivalent binding.
Using branched NT4 fragment 8–13, conjugated to various
functional units for tumor imaging and therapy,[22] we found
that NT4 conjugated to methotrexate or 5-fluoro-deoxyuridine
resulted in 60% and 50% reduction, respectively,[22–24] of tumor
growth in xenografted mice. Additionally, branched NT pep-
tides have been proven to discriminate between binding of
tumor versus healthy tissue in human surgical samples, validat-
ing neurotensin receptors as highly promising tumor biomark-
ers.[23]
Results obtained in the past for NT4 indicated that these
branched peptides are promising, novel, multifunctional,
cancer-targeting molecules. The flexibility of this synthetic ap-
proach suggested it would be possible to use the branched
NT on liposomal surfaces for specific drug delivery into tumor
cells. In this paper, we report the structure and in vitro behav-
ior of liposomes containing the cytotoxic drug Doxo that are
functionalized on the external surface with a branched moiety
containing four copies of the 8–13 NT peptide. This C-terminal
NT peptide fragment is well known for its ability in mimic the
NT peptide in receptor binding ability.[19]
Results and Discussion
Design and synthesis
A new amphiphilic molecule, NT4Lys(C18)2, (Figure 1), which
contains a lysine scaffold with a lipophilic moiety and hydro-
philic peptide sequences, has been designed and synthesized.
Two oxoethylene (H-AhOh-OH) residues, acting as spacers, and
a hydrophobic moiety based on two C18 alkyl chains, are linked
to the lysine side chain. A branched three-lysine core, with a b-
Ala spacer, is linked to the alpha amino functionality of the
lysine residue; the branched core is derivatized with four
copies of the 8–13 NT amino acidic sequence.
The 18-carbon lipophilic tails were selected to increase the
tendency of the new amphiphilic molecule to form highly
stable aggregates under physiogical conditions.[25] The
branched peptide moiety, containing four copies of the 8–13
NT peptide, was selected for its well-known ability to bind NT
receptors.[19] Chemical synthesis of NT4Lys(C18)2 was carried out
on solid phase, as shown in Scheme 1, following modified pro-
tocols of the Fmoc/t-Bu-based procedures for solid-phase pep-
tide synthesis (SPPS).[26] The orthogonally-protected lysine resi-
due was anchored to the Rink amide resin. After removal of
the Fmoc lysine side chain protecting group, two H-AhOH-OH
linkers and the hydrophobic moiety with two C18 chains were
sequentially introduced. Dde deprotection of the lysine N-ter-
minal amine functionality enabled synthesis of the branched
8–13 NT tetramer according to previously reported proce-
dures.[27] The peptide derivative was collected in good yield
after HPLC–RP purification and was analyzed by mass spec-
Figure 1. Chemical structure of the NT4Lys(C18)2 compound. Three-letter codes are used for the amino acid sequence NT8–13.
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trometry (MALDI-TOF) and HPLC to confirm compound identity
and purity.
Aggregate formation and DLS
Mixed liposomes containing the commercial phospholipid sur-
factant DOPC and the synthetic amphiphile NT4Lys(C18)2 in a
95:5 molar ratio were prepared using known sonication and
extrusion procedures.[28] Briefly, monomers were dissolved in a
choloroform/methanol mixture, and the solvent was subse-
quently evaporated. The resulting film was hydrated in 0.1m
buffered solution (pH 7.4) at room temperature. Aggregation
was successfully achieved by sonicating for 30 min and subse-
quent extrusion. Complete NT4Lys(C18)2 incorporation into
DOPC liposomes was verified by analyzing a small amount of
the liposomal solution using a Sephadex column. Presence in
the first gel filtration fractions of a peak at 275 nm, with a UV
absorbance corresponding to the Tyr residue in NT4Lys(C18)2,
confirms the presence of an NT fragment on the liposome
shell. Self-assembled DOPC liposomes were also prepared and
characterized for the purpose of comparison. Dynamic light
scattering measurements were taken for pure DOPC and
mixed DOPC-NT4Lys(C18)2 aggregates in 10 mm phosphate
buffer at pH 7.4. Both aggregate systems show monomodal
distribution, due to the translational diffusion process, with ap-
parent translational diffusion coefficients D. The Stokes–Ein-
stein equation (1) is used to evaluate the hydrodynamic radius
(RH) at infinite dilution, where D0 is the translational diffusion
coefficient at infinite dilution, KB is the Boltzmann constant, T is
the absolute temperature, and h is the solvent viscosity. Due
to the high solution dilution (C=2105m) of the studied sys-
tems, we can approximate D~D0, and Equation (1) can reason-
ably be used to estimate the RH of the aggregates.
RH ¼
KBT
6prD0
ð1Þ
The RH values found for DOPC and DOPC-NT4Lys(C18)2 lipo-
somes are 90.08.1 and 88.34.4 nm, respectively. The radius
found for the DOPC liposome is in good agreement with litera-
ture data.[29] Mixed liposomes in which a small amount (5%) of
NT peptide derivative is added to the DOPC phospholipid have
similar liposomal structure and dimension to pure DOPC lipo-
somes, as already demonstrated for pure and mixed aggre-
gates based on similar amphiphilic monomers.[28]
Doxorubicin loading and release
Doxorubicin (Doxo) was loaded into the liposome using the
pH gradient method.[30] Liposomes were prepared at pH 4.0,
and phosphate buffer was diluted to 2.5 mm because of the
poor solubility of doxorubicin in phosphate solution with the
pH range 5.0–8.5.[31] The Doxo loading content was calculated
by fluorescence measurements with subtraction of the amount
of free doxorubicin, eluted by gel filtration, from the total
amount of initial doxorubicin. The Doxo loading content value
(DLC), defined as the weight ratio of the encapsulated Doxo
versus the amount of the amphiphilic moieties, was 0.065.
Unloaded doxorubicin was removed using a Sephadex G50
column. The release profile of Doxo from liposomes was stud-
ied within 96 h using a dialysis membrane immersed in cell
medium at 37 8C. Transfer of released Doxo through the dialy-
sis membrane to buffer solution was assumed to occur rapidly,
and the release of Doxo from its liposomal vehicle to medium
was assumed to be the rate-limiting step in this process. The
amount of Doxo released was estimated by UV/vis spectrosco-
py at 480 nm, and the release profiles for DOPC-NT4Lys(C18)2-
Doxo liposomes are reported in Figure 2 as a percentage of
the total released Doxo as a function of time. As expected,
DOPC-Doxo liposomes do not show any significant differences
as compared to DOPC-NT4Lys(C18)2-Doxo liposomes (data not
shown). After 8 h, corresponding to the incubation time of the
cells in the presence of Doxo-containing liposomes, approxi-
mately 25% of Doxo was released from mixed liposomes,
Scheme 1. Peptide synthesis according to the Fmoc solid-phase protocol. Rink amide resin is schematically represented as an empty circle. Reagents and con-
ditions : a) 1. DMF/Pip (70:30), 2. Dde-Lys(Fmoc)-OH, HOBt/PyBop/DIPEA (1:1:2) ; b) 1. DMF/Pip (70:30), 2. Fmoc-AhOh, HOBt/PyBop/DIEPEA (1:1:2), (2> ) ;
c) DMF/Pip (70:30), 2. N,N-dioctadecylsuccinamic acid, HOBt/PyBop/DIPEA (1:1:2) ; d) 1. DMF/hydrazine (98:2), 2. Fmoc-b-Ala-OH, HOBt/PyBop/DIEPEA (1:1:2) ;
e) 1. DMF/Pip (70:30), 2. Fmoc-Lys(Fmoc)-OH, HOBt/PyBop/DIEPEA (1:1:2) (2) ; f) 1. DMF/Pip (70:30), Fmoc-AA-OH, HOBt/PyBop/DIPEA (1:1:2) (6).
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while t1/2 (time at which 50% of Doxo had leaked from lipo-
somes) was 35 h. These results are in agreement with data pre-
viously reported by Allen et al.[32] of Doxo release from PC/
Chol/DSPE-Peg2000 (2:1:0.1) liposomes in which t1/2 ranged
from 11.2–85.5 h, depending on the phosphatidylcholine (PC)
used in liposome formation.
Cell internalization of DOPC-NT4Lys(C18)2-Doxo liposomes
The selective internalization of NT4-derivatized liposomes, com-
pared to nude liposomes, was tested in HT29 human colon ad-
enocarcinoma and TE671 human rhabdomyosarcoma. The
HT29 cell line expresses two NT receptors, NTR1 and NTR3,
while TE671 only expresses NTR3, as confirmed by RT-PCR (Fig-
ure 3a and b). Internalization was studied by confocal micros-
copy following the red fluorescence signal of Doxo (Figure 2c
and d). Cells were incubated at a number of temperatures (4,
25, and 37 8C) for various time intervals (from 30 min–3 h). The
concentrations of liposomes, (200 nm, 400 nm, and 1 mm) were
calculated as the molarity of Doxo. Figure 3 is representative
and shows images taken after 2 h incubation with 200 nm lipo-
somes at 37 8C. At lower temperatures and all concentrations,
the internalization of both types of liposomes is slightly lower,
as expected (see Supporting Information). The internalization
process is near completion by 30 min at all temperatures and
concentrations. The intracellular red fluorescence was very
strong for cells incubated with DOPC-NT4Lys(C18)2-Doxo lipo-
somes, whereas nonfunctionalized liposomes gave very faint
signals under the same experimental conditions. A comparison
between functionalized and nude liposomes suggests an im-
portant net advantage obtained through conjugation of the
particles with branched NT.
Cytotoxicity of DOPC-NT4Lys(C18)2-Doxo liposomes
HT29 and TE671 cells were incubated with various concentra-
tions, from 8 nm–25 mm, of DOPC-NT4Lys(C18)2-Doxo liposomes
and DOPC-Doxo liposomes. After 8 h incubation, cells were
washed and incubated for six days. Washing was performed to
avoid diffusion of free Doxo from the liposomes during the six
day incubation period. As reported in Figure 4, DOPC-NT4Lys-
(C18)2-Doxo liposomes showed an EC50 value of 1.30 mm in
HT29, whereas the EC50 value of DOPC-Doxo liposomes was
5.48 mm ; therefore, the labeling of liposomes with a tumor se-
lective moiety produced a four-fold increase in activity (p<
0.05). The same increase in cytotoxicity was observed in TE671.
The cytotoxic behavior of free Doxo and empty liposomes
under the same experimental conditions (see Supporting Infor-
mation) was also investigated. As expected, Doxo cytotoxicity
is markedly higher with respect to free versus encapsulated
drug (EC50=0.323 mm), while no cytotoxicity was observed for
empty DOPC liposomes when they are studied in the 5 nm–
400 mm concentration range.
FACS analysis
HT29 and TE671 cells were incubated with various concentra-
tions (from 500 nm–10 mm) of either DOPC-NT4Lys(C18)2-Doxo
liposomes or DOPC-Doxo liposomes (Figure 5). At the highest
concentration, the difference between the two types of lipo-
Figure 2. Release of Doxo by DOPC-NT4Lys(C18)4-Doxo liposomes (*). The
amount of Doxo released was estimated by UV/vis spectroscopy at 480 nm.
Figure 3. RT-PCR expression of NT receptors in a) HT29 and b) TE671 cells,
lane 0=DNA standard, lane 1=NTR1, lane 2=NTR2, lane 3=NTR3, lane
4=beta2 microglobulin. Confocal microscopy: c) HT29 and d) TE671 cells
were incubated with DOPC-NT4Lys(C18)2-Doxo liposomes (200 nm, right) and
with DOPC-Doxo liposomes (200 nm, left) for 2 h at 37 8C. Plasma membrane
was stained with lectin-FITC (green).
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somes was maximized. In HT29, DOPC-NT4Lys(C18)2-Doxo lipo-
somes gave an increase in fluorescent signal of 40% compared
to the analogous DOPC-Doxo liposomes. In TE671 (not shown),
the NT4-derivatized liposomes showed a 20% increase in fluo-
rescence with respect to the nude analogues.
Conclusions
In vitro results achieved thus far indicate very promising per-
formance of liposomes labeled with branched NT, which may
be used for selective targeting of tumor cells. Functionalized
liposomes show a clear advantage in comparison to native lip-
osomes in tumor cell drug internalization, both in HT29 and
TE671 cells. Cytotoxicity of DOPC-NT4Lys(C18)2-Doxo liposomes
is increased four-fold with respect to DOPC-Doxo liposomes in
both HT29 and TE671 cell lines. Results from FACS analysis are
in line with these results, resulting in a fluorescence signal in-
crease of the NT4 liposomes as compared to the nude ana-
logues in both cell lines. All of these effects can be ascribed to
the fact that DOPC-NT4Lys(C18)2-Doxo liposomes have a higher
rate of internalization, due to stronger binding driven by a
lower dissociation constant of the NT4 liposomes that bind the
membrane onto a specific protein, in contrast to the nude lip-
osomes, which approach the plasma membrane unselectively.
These in vitro results can be considered very promising, in the
sense that the possibility to derivatize liposomes in order to
make them selective carriers is considered an endpoint in this
field. Selective liposomes can then be loaded with any single
chemotherapeutic or a combination of drugs to become a val-
uable weapon to fight cancer.
Experimental Section
Chemistry
Materials and instrumentation : Fmoc-protected amino acid deriv-
atives, coupling reagents, and Rink amide p-methylbenzhydryla-
mine MBHA resin were purchased from Calbiochem–Novabiochem
(Laufelfingen, Switzerland). The Fmoc-21-amino-4,7,10,13,16,19-
hexaoxaheneicosanoic acid (Fmoc-Ahoh-OH) was purchased from
Neosystem (Strasbourg, France). N,N-Dioctadecylsuccinamic acid
was synthesized according to a published procedure.[33] All other
chemicals were commercially available by Sigma–Aldrich, Fluka
(Buchs, Switzerland), or LabScan (Stillorgan, Dublin, Ireland) and
were used as received, unless otherwise stated. Preparative HPLC
was carried out on a LC8 Shimadzu HPLC system (Shimadzu Corpo-
ration, Kyoto, Japan) equipped with a UV lambda-Max Model 481
detector using a Phenomene C4 column (300 , 25021.20 mm,
5 m ; Torrance, CA), eluting with A) water/0.1% trifluoroacetic acid
(TFA) and B) CH3CN/0.1% TFA from 40–95% over 25 min at a
20 mLmin1 flow rate. Analytical HPLC was carried out using a Ju-
piter C4 column (300 , 1504.60 mm, 5 m) and the same gradient
at a 1 mLmin1 flow rate. Fluorescence spectra were recorded on a
Jasco Model FP-750 spectrofluorimeter, using a 1.0 cm path length
quartz cell. UV measurements were performed on a UV/vis Jasco V-
5505 spectrophotometer equipped with a Jasco ETC-505T Peltier
temperature controller with a 1 cm quartz cuvette (Hellma).
(8S,10S)-10-(4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-
yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-
tetra hydro-tetracene-5,12-dione; doxorubicin HCl) was purchased
from Sigma–Aldrich. 1,2-Dioleoyl-sn-glycero-3-phosphocholine
(DOPC) was purchased from Avanti Polar Lipids (Alabaster, AL,
USA). The liposomes were extruded using a mini-extruder pur-
chased from Avanti Polar Lipids. Dynamic light scattering measure-
ments were carried out by mini-DAWN TREOS Wyatt Techology
(Santa Barbara, CA, USA). Mass spectra were recorded on a matrix-
assisted laser desorption ionization-time of flight (MALDI-TOF) Voy-
ager-DE (Perseptive Biosystems).
Synthesis of (Arg-Arg-Pro-Tyr-Ile-Leu)4-(Lys)2-Lys-bAla-Lys-
(AhOH)2-(C18)2 (NT4Lys(C18)2): The monomer was synthesized on
solid phase using Rink amide (MBHA) resin (0.54 mmolg1;
0.048 mmol, 0.090 g) as polymeric support. After swelling of the
resin in 2.0 mL of N,N-dimethylformamide (DMF for 1 h, the Fmoc
protecting group was removed by a mixture of piperidine/DMF
(30:70). The carboxylic group of Dde-Lys(Fmoc)-OH (0.100 mmol,
0.532 g) was activated by 1.0 equiv of benzotriazol-1-yl-oxytris(pyr-
rolidino)phosphonium (PyBop), 1-hydroxybenzotriazole (HOBt), and
2.0 equiv of N,N-diisopropylethylamine (DIPEA) in DMF. The solu-
tion was added to the resin, and the slurry suspension was stirred
for 1 h. Coupling of the lysine residue was performed twice and
checked by the Kaiser colorimetric test. The solution was filtered
and the resin washed with three portions of DMF and three por-
tions of CH2Cl2. After the removal of the Fmoc protecting group
from the lysine side chain, two molecules of Fmoc-Ahoh-OH were
sequentially coupled according to previously described coupling
and deprotection conditions. After Fmoc deprotection, N,N-diocta-
decylsuccinamic acid (0.1 mmol, 0.62 g) was condensed, with
2.0 equiv dissolved in DMF/CH2Cl2 (50:50). The lipophilic moiety
was activated in situ by the standard HOBt/PyBop/DIPEA proce-
dure, and the coupling reaction proceeded for 1 h. The resin was
Figure 4. Cytotoxicity: a) HT29 and b) TE671 cells were incubated with vari-
ous concentrations, from 8 nm–25 mm, of DOPC-NT4Lys(C18)2-Doxo liposomes
(&) and DOPC-Doxo liposomes (*). After 8 h incubation, cells were washed
and incubated for six days. Percentage of cell survival is calculated in com-
parison to untreated controls. EC50 values: DOPC-NT4Lys(C18)2-Doxo lipo-
somes EC50=1.81 mm (HT29), EC50=1.53 mm (TE671); DOPC-Doxo lipo-
somes EC50=5.48 mm (HT29), EC50=6.72 mm (TE671).
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washed three times with DMF, then, 1-(4,4-dimethyl-2,6-dioxo-cy-
clohexylidene)3-methylbutyl (Dde) was removed from the N-termi-
nal amine functionality of the lysine residue by treatment with
DMF/hydrazine (98:2). The peptide–resin was stirred with 3.0 mL of
this solution for 10 min. The treatment was repeated twice, and
the deprotection reaction was monitored by the qualitative Kaiser
test and UV spectroscopy. The following amino acid derivatives
were coupled sequentially to the free N-terminal amine functionali-
ty using the previous described coupling and deprotection condi-
tions: Fmoc-bAla-OH, Fmoc-Lys(Fmoc)-OH, Fmoc-Lys(Fmoc)-OH,
Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Pro-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH. Finally, the N-terminal Fmoc
protecting group was removed, and the amphiphilic peptide was
cleaved with TFA containing triisopropylsylane (2.5%), and water
(2.0%) over a period of 24 h. The peptide product was precipitated
by adding water dropwise at 0 8C, purified by HPLC, and lyophi-
lized. The final product (NT4Lys(C18)2) was obtained in 25% yield
and analyzed by HPLC and MALDI-TOF mass spectroscopy: HPLC:
tR=39.2 min; MALDI-TOF: MW=5068 Da.
Aggregate preparation and DLS characterization : All solutions
were prepared by weight and buffered at pH 7.4 using 0.1m phos-
phate buffer. The pH was controlled using pH meter MeterLab
PHM220. In most cases, the samples to be measured were pre-
pared from stock solutions. Mixed aggregates of DOPC and NT4Lys-
(C18)2 (95:5 molar ratios) were prepared by dissolving the two am-
phiphiles in a small amount of MeOH/CHCl3 (50:50), subsequently
evaporating the solvent by slowly rotating the tube containing the
solution under a stream of nitrogen. In this manner, a thin film of
amphiphiles was obtained which was hydrated by addition of
0.1m phosphate buffer (pH 7.4) and sonicated for 30 min. All sam-
ples were extruded 21 times through a polycarbonate membrane
(100 nm pore size). A similar procedure was used to prepare pure
Figure 5. FACS analysis: HT29 cells were incubated with NT4-Doxo liposomes (c) and with Doxo liposomes (a). Cells were fixed for 10 min at room tem-
perature with 4% PFA-TBS and then incubated for 1 h and 0.5 h at room temperature with various concentrations of liposomes (a) 10 mm ; b) 5 mm ; c) 2.5 mm ;
d) 1 mm ; e) 500 nm). f) Fluorescent signals were measured with a BD FACSCanto II and analyzed by nonlinear regression. Differences between NT4-Doxo lipo-
somes (&) and Doxo liposomes (*) are shown.
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DOPC liposomes. All solutions were then diluted with phosphate
buffer to a final lipid concentration of 2.0105m. Samples were
centrifuged at 13,000 rpm for 5 min at room temperature, and the
measurement was performed at 25 8C. Scattered light intensities
were measured at a fixed scattering angle (q=908). Results were
processed with the Qels program (Wyatt Technology).
Doxorubicin loading : DOPC-Doxo and DOPC-NT4Lys(C18)2-Doxo lip-
osomal formulations were prepared by loading doxorubicin·HCl
into DOPC and DOPC-NT4Lys(C18)2 supramolecular aggregates, re-
spectively. Doxo was loaded using the pH gradient method with
free Doxo removed by gel filtration. Briefly, the liposomal solution
was prepared as reported above at pH 4.0 using 0.1m citrate-phos-
phate buffer. The pH was adjusted from 4.0 to 7.4 by dropwise ad-
dition of a 1.0m stock solution of NaOH. Next, 210 mL of 2.36
103m Doxo solution in 2.5 mm phosphate buffer were added to
100 mL of liposomal solution. This suspension was stirred for
30 min at room temperature. The Doxo concentration in all experi-
ments was determined by spectroscopic measurements (UV or
fluorescence) using calibration curves obtained by measuring ab-
sorbance at 480 nm or fluorescence emission at 590 nm. Emission
spectra were recorded at room temperature. Equal excitation and
emission bandwidths were used throughout experiments, with a
recording speed of 125 nmmin1 and automatic selection of the
time constant. Subsequently, unloaded Doxo was removed using a
Sephadex G50 column pre-equilibrated with 2.5 mm phosphate
buffer at pH 7.4. The Doxo loading content (DLC, defined as the
weight ratio of encapsulated Doxo versus the amphiphilic moiet-
ies) was quantified by subtraction of the amount of Doxo removed
from the total amount of Doxo loaded.
Doxorubicin release : In vitro doxorubicin release from DOPC and
DOPC-NT4Lys(C18)2 liposomes was measured using a dialysis
method. Before starting the release experiment, Doxo-loaded lipo-
somes underwent two ultracentrifugations at 34000 rpm for 3.5 h
at 4 8C using the Beckman SW55 rotor to remove free doxorubicin
from the solution. Doxo-loaded liposomes were redissolved in
water solution. 1.5 mL of Doxo-containing aggregates were added
to a dialysis bag (MW cutoff 3500), placed into 15 mL of cell media,
and incubated while stirring for 96 h at 37 8C. Aliquots (2 mL) of
the dialyzed solution was removed at various time points to mea-
sure drug content in the dialyzed solution and was replaced imme-
diately by the same volume of fresh medium. The concentration of
released Doxo was analyzed by UV/vis spectroscopy at 480 nm.
Biology
Cell cultures : HT29 human colon adenocarcinoma cells were grown
in the recommended medium, McCoy’s 5A, supplemented with
10% fetal calf serum, 200 mgmL1 glutamine, 100 mgmL1 strepto-
mycin, and 60 mgmL1 penicillin and maintained at 37 8C in 5%
CO2. Cell lines were purchased from Istituto Zooprofilattico Speri-
mentale (Brescia, Italy).
Reverse transcription PCR : Reverse transcription PCR was used for
analysis of mRNA. Total RNA was isolated using an RNeasy kit
(Qiagen) with 3106 cells, as suggested by the manufacturer. One
step reverse transcription PCR (Qiagen) was applied for retrostran-
scription and cDNA amplification of NTR1, NTR2, and NTR3. The oli-
gonucleotides used as primers are given below with the predicted
sizes of amplified fragments 291 bp, 429 bp, 552 bp, and 114 bp
for human NTR1, NTR2, NTR3, and beta2 microglobulin, respective-
ly. NTR1 sense: TCATCGCCTTTGTGGTCTGCT, antisense: TGGTTG-
CTGGACACGCTGTCG; NTR2 sense: GTCTCCTCAGCTTCATCGTAT, an-
tisense: TCCCCAAAGCCTGAAGCTGTA; NTR3 sense: AGAATGGTC-
GAGACTATGTTG, antisense: AAGAGCTATTCCAAGAGGTCC; beta2
microglobulin sense: ACCCCCACTGAAAAAGATGA, antisense ATC-
TTCAAACCTCCATGATG.
Cell binding and internalization : HT29 and TE671, plated at a densi-
ty of 25000 cells per well and incubated overnight, were fixed for
10 min in 4% para-formaldehyde (PFA)/Tris-buffered saline (TBS;
50 mm Tris, 150 mm NaCl, pH 7.4) and incubated at a number of
temperatures (4, 25, and 37 8C) for various time intervals (30 min–
3 h) with liposomes (200 nm Doxo) diluted in 0.3% bovine serum
albumin (BSA)/TBS. Cells were then washed three times with TBS
and the membranes stained with lectin/FITC 0.5 mgmL1 in 0.3%
BSA/TBS for 15 min at room temperature. Images were taken with
a TCS SP5 Leica confocal microscope.
Cytotoxicity of drug-conjugated branched NT: HT29 and TE671 cells
were plated at a density of 25000 cells per well in 96-well micro-
plates. After 24 h, cells were exposed to various concentrations of
liposomes (8 nm–25 mm). After 8 h incubation, cells were washed
and grown for six days at 37 8C in the same medium. Growth inhib-
ition was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT). EC50 values were calculated by non-linear
regression analysis using GraphPad Prism software (v. 3.02). Values
obtained from the untreated controls resulted in 100% cell viabili-
ty.
FACS analysis : HT29 cells and TE671 cells were incubated with
DOPC-Doxo and DOPC-NT4Lys(C18)2-Doxo liposomes. 100000 cells
per well were fixed for 10 min at room temperature with 4% PFA-
TBS, then incubated in 96-well U-bottomed plates for 0.5 and 1 h
at room temperature with various concentrations of liposomes
(500 nm–10 mm) in 5 mm TBS-EDTA with 0.5% BSA. Flow cytometry
measurements were obtained by analyzing 10000 events with a
FACSCanto II (BD, Franklin Lakes, NJ, USA). Results were analyzed
by nonlinear regression analysis using GraphPad Prism software.
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Target-Selective Drug Delivery
through Liposomes Labeled with
Oligobranched Neurotensin Peptides
Tag: you’re it! Labeled liposomes func-
tionalized with tetrabranched neuroten-
sin peptides may be used to selectively
target tumor cells. Functionalized lipo-
somes show clear advantages in cell
binding, doxorubicin internalization,
and cytotoxicity. Synthesis and evalua-
tion of such functionalized liposomes
are presented here as promising advan-
ces in cancer therapy.
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